Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.

@article{Sugahara2017ProlylHD,
  title={Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.},
  author={Mai Sugahara and Tetsuhiro Tanaka and Masaomi Nangaku},
  journal={Kidney international},
  year={2017},
  volume={92 2},
  pages={
          306-312
        }
}
Anemia is a common complication of chronic kidney disease and is mainly caused by the inability of injured kidneys to produce adequate amounts of erythropoietin. Studies elucidating the regulation of erythropoietin production led to the identification of hypoxia-inducible factor (HIF), which activates the transcription of genes that mediate adaptive responses to hypoxia. HIF is a heterodimer that consists of an α and β subunit. While HIF-β is constitutively expressed, HIF-α is subjected to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
3 Extracted Citations
0 Extracted References
Similar Papers